Multiple Ascending-Dose Study of EDP 322 in Healthy Adult Volunteers

NCT ID: NCT00990145

Last Updated: 2009-10-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 52 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2008-11-30
• Study Completion Date: 2009-09-30

Brief Summary

This was a Phase I, single-center, randomized, double-blind, placebo-controlled, ascending multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of orally administered EDP-322 in healthy adult volunteers.

Detailed Description

Fifty-two subjects were enrolled into 6 cohorts. Six subjects of each cohort were randomized to received EDP-322 and 2 subjects of each cohort received placebo. Each cohort received the study drug once daily (QD) for 7 days under fed conditions. Multiple oral doses of EDP 322 ranging from 200 to 800 mg were safe and generally well tolerated by the healthy male and female subjects in this study.

Conditions

MRSA, SSTI

Study Design

• Allocation Method: RANDOMIZED
• Blinding Strategy: TRIPLE

Study Groups

Intervention

EDP-322 v. Placebo

Group Type: EXPERIMENTAL

EDP-322

Intervention Type: DRUG

Interventions

EDP-322

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy adult males or females between 18 and 45 years of age
• Females are eligible if documentation exists that they are surgically sterilized
• In good general health [determined by medical history, physical examination, clinical laboratory tests, and without evidence of a clinically significant abnormality, in the opinion of the investigator and medical monitor.
• Subject has a resting 12-lead ECG at screening that shows no clinically significant abnormality and a Bazett-corrected QT interval less than 450 milliseconds.
• BMI between 18-32 kg/m2
• Subject read, understood, and signed the ICF

Exclusion Criteria

• History of chronic or recurrent renal, hepatic, pulmonary, allergic, cardiovascular, gastrointestinal, endocrine, CNS, hematologic or metabolic disease, or has an immunologic, emotional, and/or psychiatric disturbance.
• History of gastric surgery, etc.
• Abnormality or clinical lab test results at Screening that is considered clinical significant by the investigator or the medical monitor.
• Gastroenteritis within 1 week before Day 1.
• Acute illness that could pose a threat or harm to the subject or interfere with laboratory test results or interpretation of study data.
• Donated blood within a 4 week period before Day 1.
• Positive for Hep B, C or HIV-1, HIV=2, or positive results at Screening for hepatitis B surface antigen (HBsAG), HCV antibody, or HIV-1 or HIV-2 antibodies
• Medication-related exclusions

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Enanta Pharmaceuticals, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Enanta Pharmaceuticals, Inc.

Locations

PPD Phase I Unit

Austin, Texas, United States

Countries

United States

Other Identifiers

EDP-322-07-002

Identifier Type: -

Identifier Source: org_study_id